242 related articles for article (PubMed ID: 15130943)
1. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.
Kumar S; Witzig TE; Timm M; Haug J; Wellik L; Kimlinger TK; Greipp PR; Rajkumar SV
Blood; 2004 Aug; 104(4):1159-65. PubMed ID: 15130943
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.
Vacca A; Ribatti D; Presta M; Minischetti M; Iurlaro M; Ria R; Albini A; Bussolino F; Dammacco F
Blood; 1999 May; 93(9):3064-73. PubMed ID: 10216103
[TBL] [Abstract][Full Text] [Related]
3. Angiogenic cytokines profile in smoldering multiple myeloma: no difference compared to MGUS but altered compared to symptomatic myeloma.
Gkotzamanidou M; Christoulas D; Souliotis VL; Papatheodorou A; Dimopoulos MA; Terpos E
Med Sci Monit; 2013 Dec; 19():1188-94. PubMed ID: 24355943
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis in multiple myeloma.
Rajkumar SV; Kyle RA
Semin Oncol; 2001 Dec; 28(6):560-4. PubMed ID: 11740809
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR
Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422
[TBL] [Abstract][Full Text] [Related]
6. The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma.
Babarović E; Valković T; Budisavljević I; Balen I; Štifter S; Duletić-Načinović A; Lučin K; Jonjić N
Pathol Res Pract; 2016 Jun; 212(6):509-16. PubMed ID: 26997492
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow angiogenesis in multiple myeloma.
Vacca A; Ribatti D
Leukemia; 2006 Feb; 20(2):193-9. PubMed ID: 16357836
[TBL] [Abstract][Full Text] [Related]
8. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin is involved in the angiogenic potential of bone marrow macrophages in multiple myeloma.
De Luisi A; Binetti L; Ria R; Ruggieri S; Berardi S; Catacchio I; Racanelli V; Pavone V; Rossini B; Vacca A; Ribatti D
Angiogenesis; 2013 Oct; 16(4):963-73. PubMed ID: 23881169
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow angiogenesis and plasma cell angiogenic and invasive potential in patients with active multiple myeloma.
Vacca A; Ribatti D; Roccaro AM; Ria R; Palermo L; Dammacco F
Acta Haematol; 2001; 106(4):162-9. PubMed ID: 11815713
[TBL] [Abstract][Full Text] [Related]
11. Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients.
Lamanuzzi A; Saltarella I; Ferrucci A; Ria R; Ruggieri S; Racanelli V; Rao L; Annese T; Nico B; Vacca A; Ribatti D
Oncotarget; 2016 Mar; 7(12):14510-21. PubMed ID: 26919105
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
Andersen NF; Kristensen IB; Preiss BS; Christensen JH; Abildgaard N
Eur J Haematol; 2015 Sep; 95(3):211-7. PubMed ID: 25353275
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma.
Sezer O; Jakob C; Eucker J; Niemöller K; Gatz F; Wernecke K; Possinger K
Eur J Haematol; 2001 Feb; 66(2):83-8. PubMed ID: 11168514
[TBL] [Abstract][Full Text] [Related]
14. Elevated level of plasma basic fibroblast growth factor in multiple myeloma correlates with increased disease activity.
Sato N; Hattori Y; Wenlin D; Yamada T; Kamata T; Kakimoto T; Okamoto S; Kawamura C; Kizaki M; Shimada N; Ote Y; Hata J; Ikeda Y
Jpn J Cancer Res; 2002 Apr; 93(4):459-66. PubMed ID: 11985797
[TBL] [Abstract][Full Text] [Related]
15. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
[TBL] [Abstract][Full Text] [Related]
16. Antimyeloma effects of resveratrol through inhibition of angiogenesis.
Hu Y; Sun CY; Huang J; Hong L; Zhang L; Chu ZB
Chin Med J (Engl); 2007 Oct; 120(19):1672-7. PubMed ID: 17935668
[TBL] [Abstract][Full Text] [Related]
17. The evaluation of angiogenesis and matrix metalloproteinase-2 secretion in bone marrow of multiple myeloma patients before and after the treatment.
Bolkun L; Lemancewicz D; Sobolewski K; Mantur M; Semeniuk J; Kulczynska A; Kloczko J; Dzieciol J
Adv Med Sci; 2013; 58(1):118-25. PubMed ID: 23333895
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow angiogenesis in patients with active multiple myeloma.
Vacca A; Ribatti D; Roccaro AM; Frigeri A; Dammacco F
Semin Oncol; 2001 Dec; 28(6):543-50. PubMed ID: 11740807
[TBL] [Abstract][Full Text] [Related]
19. Angiogenesis in multiple myeloma.
Jakob C; Sterz J; Zavrski I; Heider U; Kleeberg L; Fleissner C; Kaiser M; Sezer O
Eur J Cancer; 2006 Jul; 42(11):1581-90. PubMed ID: 16797965
[TBL] [Abstract][Full Text] [Related]
20. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma.
Scavelli C; Nico B; Cirulli T; Ria R; Di Pietro G; Mangieri D; Bacigalupo A; Mangialardi G; Coluccia AM; Caravita T; Molica S; Ribatti D; Dammacco F; Vacca A
Oncogene; 2008 Jan; 27(5):663-74. PubMed ID: 17667938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]